Leslie Chong
Chief Executive Officer chez IMUGENE LIMITED
Fortune : 5 M $ au 31/03/2024
Profil
Leslie Chong is currently the Chief Executive Officer, MD & Director at Imugene Ltd.
Prior to this, Ms. Chong held positions as Director at Cure Brain Cancer Foundation from 2020 to 2023, Independent Non-Executive Director at Chimeric Therapeutics Ltd.
(Australia) from 2020 to 2023, and had roles in the Clinical Operation Department at Pharmaceutical Product Development LLC, Exelixis, Inc., and GSK Plc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMUGENE LTD
1,09% | 12/01/2024 | 79 916 666 ( 1,09% ) | 5 M $ | 31/03/2024 |
| 30/06/2023 | 46 205 ( 0,01% ) | 904 $ | 31/03/2024 |
Postes actifs de Leslie Chong
| Sociétés | Poste | Début |
|---|---|---|
| IMUGENE LIMITED | Chief Executive Officer | 01/11/2016 |
Anciens postes connus de Leslie Chong
| Sociétés | Poste | Fin |
|---|---|---|
| CHIMERIC THERAPEUTICS LIMITED | Director/Board Member | 12/07/2023 |
Cure Brain Cancer Foundation
 Cure Brain Cancer Foundation Miscellaneous Commercial ServicesCommercial Services Cure Brain Cancer Foundation is a non-profit organization based in Australia that is dedicated to funding innovative brain cancer research. The private company is based in Sydney, Australia. The foundation has invested over $30 million into brain cancer research, including clinical trials and pre-clinical research efforts across pediatric and adult brain cancers. The foundation passionately forges research collaborations, brings world-class clinical trials, and gives people with brain cancer greater access to innovative new treatments. The foundation's mission is to unite the community and rapidly increase brain cancer survival, improving the quality of life for people impacted by the disease, with a vision to ultimately find a cure for brain cancer. The Australian company was founded in 2001. Lance Kawaguchi has been the CEO of the company since 2021. | Director/Board Member | 11/04/2023 |
| GSK PLC | Corporate Officer/Principal | 01/01/2006 |
| EXELIXIS, INC. | Corporate Officer/Principal | - |
Pharmaceutical Product Development LLC
 Pharmaceutical Product Development LLC Miscellaneous Commercial ServicesCommercial Services Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| GSK PLC | Health Technology |
| IMUGENE LIMITED | Health Technology |
| Entreprise privées | 3 |
|---|---|
Pharmaceutical Product Development LLC
Pharmaceutical Product Development LLC Miscellaneous Commercial ServicesCommercial Services Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC. | Commercial Services |
Cure Brain Cancer Foundation
Cure Brain Cancer Foundation Miscellaneous Commercial ServicesCommercial Services Cure Brain Cancer Foundation is a non-profit organization based in Australia that is dedicated to funding innovative brain cancer research. The private company is based in Sydney, Australia. The foundation has invested over $30 million into brain cancer research, including clinical trials and pre-clinical research efforts across pediatric and adult brain cancers. The foundation passionately forges research collaborations, brings world-class clinical trials, and gives people with brain cancer greater access to innovative new treatments. The foundation's mission is to unite the community and rapidly increase brain cancer survival, improving the quality of life for people impacted by the disease, with a vision to ultimately find a cure for brain cancer. The Australian company was founded in 2001. Lance Kawaguchi has been the CEO of the company since 2021. | Commercial Services |
| Chimeric Therapeutics Ltd. (Australia) |
